Metis TechBio and Boulevard Bio's Landmark Deal

Metis TechBio, a drug design tech firm listed in Hong Kong, has entered a deal with U.S.-based Boulevard Bio, granting exclusive rights to its autoimmune drug MTS-128. The agreement, valued at $1.6 billion, signifies progress in U.S.-China tech collaborations amid increased scrutiny on cross-border deals.

Metis TechBio, a Hong Kong-listed tech firm specializing in drug design, announced a significant development on Tuesday. The company has formed a pivotal agreement with Boulevard Bio, a biotechnology firm based in the United States, granting it exclusive worldwide rights to develop, produce, and market Metis TechBio's novel autoimmune drug, MTS-128.

This agreement could be worth up to $1.6 billion, marking a significant step in the field of biotechnology. The deal reflects a growing trend in collaboration between U.S. and Chinese tech companies, even as Beijing intensifies its scrutiny of international technology contracts involving potentially sensitive innovations.

This partnership underscores the continued potential for cross-border innovation in the face of geopolitical challenges, emphasizing the importance of strategic alliances in advancing medical technology development globally.